| |
|
|
|
|
|
|
|
|
|
AbCellera-Discovered Antibody, Bamlanivimab, Administered with Etesevimab Receives FDA Emergency Use Authorization for COVID-19
|
|
Vancouver, BC, February 18, 2021--AbCellera (Nasdaq: ABCL) announced that bamlanivimab (LY-CoV555) 700 mg, a human antibody discovered by AbCellera and developed with Eli Lilly and Company (Lilly), administered with a second Lilly antibody, etesevimab (LY-CoV016) 1400 mg, has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the treatment of mild to moderate COVID-19 in patients aged 12 and older who are at high risk for progressing to severe COVID-19 and/or hospitalization.
|
|
|
|
|
|
|
|
AbCellera Appoints Ester Falconer, Ph.D., as Chief Technology Officer
|
|
Vancouver, BC, February 12, 2021--AbCellera (Nasdaq: ABCL) announced that Ester Falconer, Ph.D., has been appointed as Chief Technology Officer (CTO), effective immediately. As CTO, Dr. Falconer will lead AbCellera's long-term strategy in the development, aggregation, and integration of technologies that improve the speed and success of therapeutic antibody discovery from target to investigational new drug application submission.
|
|
|
|
|
|
|
|
AbCellera-Discovered Antibody, Bamlanivimab, to be Developed with VIR-7831 for the Treatment of COVID-19
|
|
Vancouver, BC, February 8, 2021--AbCellera (Nasdaq: ABCL) announced that bamlanivimab (LY-CoV555), a human antibody discovered by AbCellera and developed with Eli Lilly and Company (Lilly), will be evaluated together with VIR-7831, an antibody developed by Vir Biotechnology, Inc. and GlaxoSmithKline, as a potential COVID-19 therapy in low-risk patients with mild to moderate COVID-19.
|
|
|
|
|
|
|
|
|
|
|
|
|
News
Events
Tech Careers
Directory
Tech Stocks
T-Net 100
Members
Feedback
About T-Net
Employers
Post Job Listings
Advertise
